ÂÜÀòÂÒÂ×

Verl Sriskanda has extensive experience in the biopharmaceutical field, currently serving as Analytical Lead for Vaccine Programs and Group Leader for Bioassays at Pfizer since November 2001. Responsibilities include overseeing Assays Development, Qualification, Validation, Characterization, and Technology Transfer to support clinical trials for Antibody-Drug Conjugates targeting cancer patients. Additionally, Verl previously held the role of Associate Director-I and Group Leader, focusing on Drug Product Analytical Methods Development for the Prevnar13® vaccine. Prior to Pfizer, Verl worked as a Post Doctoral Research Fellow at Memorial Sloan-Kettering Cancer Center, studying DNA Ligase functions in DNA damage recognition and repair. Academic qualifications include a Ph.D. in Molecular Biology from the University of South Carolina and studies at Indiana State University.